|
Bailey McCann, Opalesque New York: EQT Life Sciences has held the final close of its inaugural LSP Dementia Fund raising approximately EUR 260 million in fee-generating assets under management, meeting the hard cap and surpassing the target fund size of EUR 100 million.
The fund is dedicated to investing in companies that are developing breakthrough drug therapies and medical technologies across the spectrum of neurodegenerative diseases.
The LSP Dementia Fund investment team is led by Philip Scheltens, MD, PhD, professor emeritus at Amsterdam University Medical Center and one of the world's most renowned dementia researchers, having (co)authored over 1100 scientific publications. The other partners in the investment team are Felice Verduyn-van Weegen, MBA, Cillian King, PhD, and Arno de Wilde, MD, PhD, MBA.
The Fund is supported by a broad range of investors including the Alzheimer's Association, the European Investment Fund, and several global pharmaceutical companies. Other investors include endowments, foundations, and other private wealth investors.
The Fund intends to invest in 10 to 15 companies in total. It has already invested in NewAmsterdam Pharma, which focuses on cardiovascular and Alzheimer's disease. As well as four other companies: Muna Therapeutics (Alzheimer's disease and Parkinson's disease), AviadoBio (Frontotemporal Dementia (FTD) and Amyotrophic lateral sclerosis (ALS)), Nobi (smart care solutions in nursing homes...................... To view our full article Click here
|
RSS
